OCX - OncoCyte Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
2.35
-0.20 (-7.84%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.55
Open2.50
Bid0.00 x 2900
Ask0.00 x 1200
Day's Range2.35 - 2.55
52 Week Range1.10 - 7.64
Volume42,557
Avg. Volume105,673
Market Cap95.56M
Beta3.45
PE Ratio (TTM)N/A
EPS (TTM)-0.60
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.19
Trade prices are not sourced from all markets
  • Associated Press3 days ago

    OncoCyte: 2Q Earnings Snapshot

    On a per-share basis, the Alameda, California-based company said it had a loss of 12 cents. In the final minutes of trading on Tuesday, the company's shares hit $2.85. A year ago, they were trading at ...

  • GlobeNewswire3 days ago

    OncoCyte Reports Second Quarter 2018 Financial Results and Positive Corporate Developments

    -Encouraging Study Data Drives Continued Development of DetermaVu™ Lung Cancer Diagnostic Test-. -Conference Call Today at 4:30 pm ET-. ALAMEDA, Calif., Aug. 14, 2018-- OncoCyte Corporation, a developer ...

  • Who Are The Major Shareholders In OncoCyte Corporation (NYSEMKT:OCX)?
    Simply Wall St.4 days ago

    Who Are The Major Shareholders In OncoCyte Corporation (NYSEMKT:OCX)?

    In this article, I will take a quick look at OncoCyte Corporation’s (NYSEMKT:OCX) recent ownership structure – an unconventional investing subject, but an important one. A company’s ownership structure isRead More...

  • GlobeNewswire8 days ago

    Seasoned Healthcare Executive Albert P. Parker Appointed Chief Operating Officer of OncoCyte

    ALAMEDA, Calif., Aug. 09, 2018-- OncoCyte Corporation, a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the appointment of Albert P. Parker, a seasoned ...

  • GlobeNewswire19 days ago

    OncoCyte to Report Second Quarter 2018 Financial Results on August 14, 2018

    ALAMEDA, Calif., July 30, 2018-- OncoCyte Corporation, a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced today that it will release its financial and operating ...

  • GlobeNewswire22 days ago

    OncoCyte Announces At-Market $3.59 Million Offering of Common Stock and Warrants

    OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy diagnostic tests for the early detection of cancer, today announced that it has entered into definitive agreements with certain investors led by members of management and the Board of Directors as well as a new institutional investor for the purchase of units, with each consisting of one share of its common stock and one warrant to acquire one share of its common stock. The warrants have an exercise price of $3.00 per share of common stock, will become exercisable six months after the date of issue, and will expire five years after the date they become exercisable. OncoCyte intends to use the net proceeds from the offering for working capital including continued development of DetermaVu™, OncoCyte’s confirmatory lung cancer diagnostic test, and other general corporate purposes.

  • See what the IHS Markit Score report has to say about OncoCyte Corp.
    Markitlast month

    See what the IHS Markit Score report has to say about OncoCyte Corp.

    Short interest is low for OCX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding OCX totaled $877 million.

  • OncoCyte (OCX) in Focus: Stock Moves 13.1% Higher
    Zackslast month

    OncoCyte (OCX) in Focus: Stock Moves 13.1% Higher

    OncoCyte (OCX) was a big mover last session, as the company saw its shares rise more than 13% on the day.

  • ACCESSWIRElast month

    Today's Research Reports on Stocks to Watch: Loxo Oncology and OnoCyte

    NEW YORK, NY / ACCESSWIRE / July 11, 2018 / Shares of Loxo Oncology were in the red on Tuesday almost 6% despite any news. Shares of OncoCyte were gaining full speed after announcing that the DetermaVu diagnostic test for lung cancer saw better performance than the company was expecting. Loxo Oncology, Inc. shares closed down almost 6% on Tuesday with around 1 million shares traded.

  • InvestorPlacelast month

    OncoCyte (OCX) Stock Skyrockets on Lung Cancer Test Study Results

    The California-based company announced that its DetermaVu diagnostic test for lung cancer churned out a better performance than the company was expecting. OncoCyte’s impressive results have encouraged the company to move DetermaVu to a different and better testing platform that would help “resolve the inconsistent data issues” that plagued the company in previous versions of the biopsy test, according to its press release. The company had to previously delay the test’s clinical validation study that launched in November 2017 as test results came back as irregular due to a “variance in the lots of consumables” of the blood sample-testing system, according to OncoCyte’s 2017 annual earnings report.

  • TheStreet.comlast month

    OncoCyte Surges on 'Encouraging' Results for Diagnostic Test for Cancer

    soared by more than 40% after the company released "encouraging" test results for its lung cancer blood diagnostic test. Shares rose $1.33 -- or 43.25% -- to $4.41 in early trading Tuesday after OncoCyte announced that its DetermaVu diagnostic test for lung cancer performed better than the company expected it would. The results of the study justify moving DetermaVu to a different and better testing platform that would "resolve the inconsistent data issues" OncoCyte dealt with in previous versions of the biopsy test, according to the release.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 9) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Arrowhead Pharmaceuticals ...

  • GlobeNewswirelast month

    OncoCyte Reports Encouraging New Study Results for Lung Cancer Blood Test

    OncoCyte Corporation (NYSE American:OCX), a developer of novel tests for early detection of cancer, today reported that its most recent study of clinical samples in the development of DetermaVu™, its lung cancer diagnostic blood test, has produced encouraging results. This study supports moving the test to a leading clinical diagnostic testing platform and indicates that the clinical performance of the test may be better than was previously expected. The move to a leading diagnostic testing platform is expected to resolve the inconsistent data issues OncoCyte encountered with the diagnostic testing platform it had previously used in the development of DetermaVu™.

  • OncoCyte Sees Hammer Chart Pattern: Time to Buy?
    Zacks2 months ago

    OncoCyte Sees Hammer Chart Pattern: Time to Buy?

    OncoCyte Sees Hammer Chart Pattern: Time to Buy?

  • Envision Healthcare to Go Private With Acquisition by KKR
    Zacks2 months ago

    Envision Healthcare to Go Private With Acquisition by KKR

    Envision Healthcare to become a private company on acquisition by private equity company KKR.

  • See what the IHS Markit Score report has to say about OncoCyte Corp.
    Markit2 months ago

    See what the IHS Markit Score report has to say about OncoCyte Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Teladoc (TDOC) Buys Advance Medical to Boost Global Presence
    Zacks2 months ago

    Teladoc (TDOC) Buys Advance Medical to Boost Global Presence

    Teladoc's (TDOC) purchase of Advance Medical is in sync with its strategy to lap up complementary businesses and expedite growth.

  • Can The Uptrend Continue for OncoCyte (OCX)?
    Zacks3 months ago

    Can The Uptrend Continue for OncoCyte (OCX)?

    Investors certainly have to be happy with OncoCyte Corporation (OCX) and its short term performance

  • Associated Press3 months ago

    OncoCyte: 1Q Earnings Snapshot

    On a per-share basis, the Alameda, California-based company said it had a loss of 12 cents. In the final minutes of trading on Tuesday, the company's shares hit $2.40. A year ago, they were trading at ...

  • See what the IHS Markit Score report has to say about OncoCyte Corp.
    Markit4 months ago

    See what the IHS Markit Score report has to say about OncoCyte Corp.

    Short interest is low for OCX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $1.32 billion over the last one-month into ETFs that hold OCX are not among the highest of the last year and have been slowing.

  • Associated Press5 months ago

    OncoCyte reports 4Q loss

    On a per-share basis, the Alameda, California-based company said it had a loss of 13 cents. For the year, the company reported that its loss widened to $19.4 million, or 64 cents per share. In the final ...

  • Investing Focused in Canada, U.S. and Europe, Says Onex CEO
    Bloomberg Video3 months ago

    Investing Focused in Canada, U.S. and Europe, Says Onex CEO

    May.16 -- Onex CEO, Gerry Schwartz, discusses where the private equity firm is headed during this time of heavy valuations and low rates. He speaks with Amanda Lang on "Bloomberg Markets."